Secondary Lymphedema Due to Human Adjuvant Disease

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

July 1, 2017

Study Completion Date

December 1, 2017

Conditions
Lymphedema, SecondaryLymphedema of LegGranuloma, Foreign-Body
Interventions
DIAGNOSTIC_TEST

Lower extremity Lymphoscintigraphy

Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points

Trial Locations (1)

10700

Hospital Angeles Pedregal, Mexico City

All Listed Sponsors
lead

Hospital Angeles del Pedregal

OTHER

NCT04588493 - Secondary Lymphedema Due to Human Adjuvant Disease | Biotech Hunter | Biotech Hunter